Peter Forsyth, MD, discusses a first-in-human trial of intrathecal dendritic cell therapy for leptomeningeal disease from breast cancer.
|Articles|August 1, 1997
Oncology NEWS International
- Oncology NEWS International Vol 6 No 8
- Volume 6
- Issue 8
AIDS Deaths Fall by 19% in United States
WASHINGTON--The number of deaths from AIDS has fallen 19%, from 37,900 in the first nine months of 1995 to 30,700 for the same time period in 1996, the Centers for Disease Control and Prevention (CDC) has announced. And, for the first time, the number of AIDS-related deaths has dropped among women, albeit by only 7%, as compared to 22% among men.
Advertisement
WASHINGTON--The number of deaths from AIDS has fallen 19%, from 37,900in the first nine months of 1995 to 30,700 for the same time period in1996, the Centers for Disease Control and Prevention (CDC) has announced.And, for the first time, the number of AIDS-related deaths has droppedamong women, albeit by only 7%, as compared to 22% among men.
The heartening news appears to be due primarily to new drug therapiesdeveloped to combat the virus and to treat AIDS-related complications,as well as improved access to medical care.
The greatest decrease was among white patients (28%), compared with16% for Hispanics and 10% for blacks.
Articles in this issue
about 29 years ago
Two-Step Approach Urged to Avoid High Tech, Wild Deathabout 29 years ago
Health Insurance Premiums Tax Proposedabout 29 years ago
ODAC Votes Yes on Taxol for Kaposi's Sarcomaabout 29 years ago
Five Principles Help Resolve Ethical Dilemmas in Careabout 29 years ago
Ovarian Cancer Survivors Form National Coalitionabout 29 years ago
Photodynamic Therapy Used in Nonmelanoma Skin Cancerabout 29 years ago
Increased Numbers of Nevi Can Predict Risk of Melanomaabout 29 years ago
With Genetic Tests, Informed Consent Enters Psychosocial Realmabout 29 years ago
Cryoablation May Have Limited Role in Prostate Cancer Treatmentabout 29 years ago
Americans Not Convinced of Value of Watchful WaitingAdvertisement
Related to this article
Adding radiotherapy to tislelizumab and chemotherapy also appeared to prolong progression-free survival in a real-world setting.
![“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/06df696db42b151710c58727b1333ee098de6453-1200x800.jpg?w=350&fit=crop&auto=format)
“[E]ven if patients relapse following an allogeneic transplant, donor lymphocyte infusions can be incredibly helpful,” said Mary Jo Lechowicz, MD.
The Community Oncology Alliance is urging CMS and Congress to address Medicare Part B drug negotiation policies that threaten independent cancer practices and patient access.
In a phase 1 trial, the MVA-vectored neoantigen vaccine TG4050 produced no dose-limiting toxicities or relapses in those with resected HPV-negative HNSCC.
At SOHO 2026, experts highlighted new findings and advances across diseases including lymphoma, myelodysplastic syndrome, and leukemia.
Poster sessions at WCLC 2026 detail how surgery, nursing, and pathology can contribute to the multidisciplinary care of patients with lung cancer.
A positive CHMP opinion supports the perioperative use of pembrolizumab plus enfortumab vedotin in resectable MIBC regardless of cisplatin eligibility.
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
FDA Approves Imlunestrant Combo in ESR1-Mutated Breast Cancer
4
Pembrolizumab/Enfortumab Vedotin Earns Positive CHMP Opinion in MIBC
5